Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HR+, HER2-, Advanced Breast Cancer: early-phase trial registry
3 of 3 indexed HR+, HER2-, Advanced Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
HR+, HER2-, Advanced Breast Cancer: 3 US clinical trials tracked, 3 recruiting.
HR+, HER2-, Advanced Breast Cancer is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Avenzo Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition hr-her2-advanced-breast-cancer
OPEN 3 | RECR 100% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
HR+, HER2-, Advanced Breast Cancer lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HR+, HER2-, Advanced Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HR+, HER2-, Advanced Breast Cancer is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics
NCT05867251
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
Avenzo Therapeutics
NCT06998407
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Marengo Therapeutics
NCT06827613
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on HR+, HER2-, Advanced Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HR+, HER2-, Advanced Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HR+, HER2-, Advanced Breast Cancer page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 HR+, HER2-, Advanced Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Avenzo Therapeutics sponsors the most HR+, HER2-, Advanced Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Avenzo Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HR+, HER2-, Advanced Breast Cancer condition card totals 3 registered trials; most-linked intervention AVZO-021; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.